Remestemcel-L not checked

Mesoblast, Inc.

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
1 active
12 in total
Targets
—
None known yet

What this is

How it works
A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
How it’s given
“Remestemcel-L is comprised of ex-vivo cultured adult human MSC”In the company’s words, NCT07568535 on ClinicalTrials.gov
Tested for
GVHD - Graft-Versus-Host Disease
Main trialPhase 3
“This study is a randomized, double-blind, placebo-controlled, multicenter Phase III trial to compare the efficacy and safety of remestemcel-L-rknd (remestemcel-L), ex-vivo cultured adult human mesenchymal stromal cells (MSC), combined with ruxolitinib vs. ruxolitinib combined with placebo as second-line therapy in adult patients with Grade III-IV steroid-refractory acute graft-versus-host disease (SR-aGVHD).”In the company’s words, NCT07568535 on ClinicalTrials.gov
Other names
Prochymal · Adult Human Mesenchymal Stem Cells · hMSCs · Mesenchymal Stem Cells

Other drugs for GVHD - Graft-Versus-Host Disease

All 24 drugs for GVHD - Graft-Versus-Host Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 28 Feb 2028 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease
Phase 3Completed 26 Dec 2008 Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)
Phase 3Completed 14 Jul 2009 Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)
Phase 3Completed 15 Sep 2014 Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Phase 3Completed 15 Sep 2014 Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Phase 3Completed 9 Apr 2018 A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
Phase 3Completed 15 Jun 2018 Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Phase 2Completed 25 Apr 2006 Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants
Phase 2Completed 28 Jul 2006 Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
Phase 2Completed 9 Mar 2009 PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2Completed 12 Dec 2010 PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
Phase 2Completed 18 May 2011 Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Remestemcel-L

Following is part of Solo: you see every change to Remestemcel-L the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in